| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT04941365) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 |
| A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (NCT05338619) | Sung Yong Lee | 2022-06-30 |
| Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment (NCT05382052) | Fundación GECP | 2022-06-17 |
| A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer (NCT05414630) | Anhui Provincial Cancer Hospital | 2022-06-01 |
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (NCT05398094) | Fundación GECP | 2022-03-21 |
| Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (NCT04765709) | Mario Negri Institute for Pharmacological Research | 2021-09-24 |
| Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (NCT04585477) | Stanford University | 2021-04-08 |
| Accelerated Radio-Immunotherapy for Lung Cancer (NCT04577638) | Center Eugene Marquis | 2021-03-30 |
| Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (NCT04716946) | Memorial Sloan Kettering Cancer Center | 2021-01-27 |
| Dose-painting Radiation for LA-NSCLC (NCT05031533) | Sichuan Cancer Hospital and Research Institute | 2021-01-01 |
| Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC (NCT04586465) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2020-10-10 |
| Efficacy and Safety of CRT, Durvalumab and Surgery for SST (NCT04465968) | National Cancer Center Hospital East | 2020-09-01 |
| A Real-world Study of Durvalumab for Lung Cancer in China (NCT04672759) | Peking Union Medical College Hospital | 2020-07-28 |
| Tumor Mutational Burden in Lung Cancer Patients (NCT04289259) | Assistance Publique - Hôpitaux de Paris | 2020-06-10 |
| Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (NCT04392505) | Oslo University Hospital | 2020-05-11 |
| The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT (NCT06015815) | Ankara University | 2019-10-05 |
| Her2-positive Lung Cancer Treated With Dedicated Drug (NCT03845270) | Intergroupe Francophone de Cancerologie Thoracique | 2019-05-17 |
| Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） (NCT03743129) | Anhui Shi, MD | 2019-04-12 |
| A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer (NCT03728556) | CStone Pharmaceuticals | 2018-10-26 |
| A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (NCT03521154) | AstraZeneca | 2018-07-19 |
| High Intensity Functional Image Guided Vmat Lung Evasion (NCT03569072) | Peter MacCallum Cancer Centre, Australia | 2018-07-01 |
| Oncoxin® and Quality of Life in Cancer Patients (NCT03550482) | Catalysis SL | 2017-11-01 |
| Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC (NCT03055715) | Martin-Luther-Universität Halle-Wittenberg | 2017-04-01 |
| ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC (NCT02946216) | First People's Hospital of Hangzhou | 2016-11-01 |
| EGFR Mutations on ctDNA in Patients With Advanced NSCLC (NCT02623257) | First People's Hospital of Hangzhou | 2016-01-01 |
| Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (NCT02622581) | AIO-Studien-gGmbH | 2015-12-01 |
| NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma (NCT02434081) | ETOP IBCSG Partners Foundation | 2015-11-25 |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT02412371) | AbbVie | 2015-04-30 |
| T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure (NCT02418234) | First People's Hospital of Hangzhou | 2015-03-01 |
| An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries (NCT02247713) | The Netherlands Cancer Institute | 2014-09-01 |
| Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer (NCT02053285) | Rush University Medical Center | 2014-01-01 |
| Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation (NCT01683175) | Tianjin Medical University Cancer Institute and Hospital | 2012-08-01 |
| Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs (NCT01346280) | National Cancer Institute (NCI) | 2011-04-16 |
| Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) (NCT00903942) | University of Rochester | 2008-03-01 |